Efficacy Of Bendamustine and Rituximab In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

被引：0
|
作者：
Kataeva, Elena
Golenkov, Anatoly
Triphonova, Elena
Dudina, Galina
Mitina, Tatyana
Lutskaya, Tatyana
Vysotskaya, Ludmila
Chernykh, Yulliya
Zakharov, Sergey
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.5312.5312
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5312
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
    Furman, Richard R.
    Sharman, Jeff P.
    Coutre, Steven E.
    Cheson, Bruce D.
    Pagel, John M.
    Hillmen, Peter
    Barrientos, Jacqueline C.
    Zelenetz, Andrew D.
    Kipps, Thomas J.
    Flinn, Ian
    Ghia, Paolo
    Eradat, Herbert
    Ervin, Thomas
    Lamanna, Nicole
    Coiffier, Bertrand
    Pettitt, Andrew R.
    Ma, Shuo
    Stilgenbauer, Stephan
    Cramer, Paula
    Aiello, Maria
    Johnson, Dave M.
    Miller, Langdon L.
    Li, Daniel
    Jahn, Thomas M.
    Dansey, Roger D.
    Hallek, Michael
    O'Brien, Susan M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (11): : 997 - 1007
  • [32] Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia
    Ghia, Paolo
    Scarfo, Lydia
    Perez, Susan
    Pathiraja, Kumudu
    Derosier, Martha
    Small, Karen
    Sisk, Christine McCrary
    Patton, Nigel
    BLOOD, 2017, 129 (13) : 1876 - 1878
  • [33] ASCEND Phase 3 Study of Acalabrutinib vs Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 21 - 22
  • [34] Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Kipps, Thomas J.
    Wierda, William G.
    Jones, Jeffrey A.
    Swinnen, Lode J.
    Yang, Jianning
    Cui, Yue
    Busman, Todd
    Krivoshik, Andrew
    Enschede, Sari
    Humerickhouse, Rod
    BLOOD, 2010, 116 (21) : 1019 - 1019
  • [35] Combination Trial of Duvelisib (IPI-145) with Bendamustine, Rituximab, or Bendamustine/Rituximab in Patients with Lymphoma or Chronic Lymphocytic Leukemia
    Flinn, Ian W.
    Cherry, Mohamad
    Maris, Michael
    Matous, Jeffrey V.
    Berdeja, Jesus G.
    Patel, Manish R.
    BLOOD, 2015, 126 (23)
  • [36] NAVITOCLAX (ABT-263) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE/RITUXIMAB (FCR) OR BENDAMUSTINE/RITUXIMAB (BR): A PHASE 1 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Kipps, T.
    Swinnen, L.
    Wierda, W.
    Jones, J.
    Coutre, S.
    Smith, M.
    Yang, J.
    Cui, Y.
    Chyla, B.
    Busman, T.
    Enschede, S.
    Humerickhouse, R.
    HAEMATOLOGICA, 2012, 97 : 219 - 219
  • [37] Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Kipps, Thomas J.
    Swinnen, Lode J.
    Wierda, William G.
    Jones, Jeffrey Alan
    Coutre, Steven E.
    Smith, Mitchell R.
    Yang, Jainning
    Cui, Yue
    Busman, Todd
    Enschede, Sari
    Humerickhouse, Rod
    BLOOD, 2011, 118 (21) : 1669 - 1669
  • [38] Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
    Badoux, Xavier C.
    Keating, Michael J.
    Wen, Sijin
    Wierda, William G.
    O'Brien, Susan M.
    Faderl, Stefan
    Sargent, Rachel
    Burger, Jan A.
    Ferrajoli, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (05) : 584 - 591
  • [39] A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)
    Nabhan, C
    Patton, D
    Gordon, LI
    Riley, MB
    Kuzel, T
    Tallman, MS
    Rosen, ST
    LEUKEMIA & LYMPHOMA, 2004, 45 (11) : 2269 - 2273
  • [40] Rituximab® and high dose methylprednisolone (HDMP) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
    Castro, JE
    Bole, J
    Prada, CE
    Kipps, TJ
    BLOOD, 2004, 104 (11) : 690A - 690A
12345